» Articles » PMID: 36788352

Long-term Outcomes of Extracorporeal Shock Wave Therapy for Acute Peyronie's Disease: a 10-year Retrospective Analysis

Overview
Journal Int J Impot Res
Date 2023 Feb 14
PMID 36788352
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this paper was to describe the long-term outcomes of extracorporeal shock wave therapy (ESWT) in patients with acute Peyronie'disease (PD). An observational retrospective study was conducted in men with acute PD who underwent ESWT between 2009-2013 at a single institution. ESWT protocol consisted of 1 session (3000 shock waves, 0.10-0.25 mJ/mm^2, 4-6 Hz) per week for 4 weeks. Penile pain was chosen as the primary outcome. Penile curvature angle, erectile function, and satisfaction with ESWT were selected as secondary long-term outcomes. A total of 194 patients were included. The mean follow-up duration after ESWT was 125.6 months. Mean penile curvature worsened significantly at 3 months (18.3 vs. 21.5 degrees; p = 0.023) and 12 months (21.5 vs. 28.6 degrees; p = 0.001) and stabilized over the long-term (28.6 vs. 28.8 degrees; p = 0.335). Mean penile pain improved significantly at 3 months (6.5 vs. 3.1 points; p < 0.001) and 12 months (3.1 vs. 1.0 points; p = 0.001), remaining stable over time (1.0 vs. 1.0 points; p = 0.074). The mean five-item version of the International Index of Erectile Function (IIEF-5) increased significantly at 3 months (14.5 vs. 17.9 points; p = 0.001), remaining stable at 12 months (17.9 vs. 18.5 points; p = 0.082), and deteriorating in the long-term (18.5 vs. 15.8 points; p = 0.003). A high satisfaction rate with ESWT was recorded at 3 months (92.3%), remaining similar at 12 months (91.2%) and over the long-term (90.2%). No new acute phase and low rate of PD surgery (4.1%) were recorded in the long-term analysis. In patients with acute PD, ESWT seems to be associated with early and persistent relief of penile pain, transient improvement in erectile function, no significant effect on penile curvature, and a high rate of patient satisfaction constant over time.

Citing Articles

Acute Phase Peyronie's Disease: Where Do We Stand?.

Douroumis K, Kotrotsios K, Katsikatsos P, Moulavasilis N, Fragkiadis E, Mitropoulos D Cureus. 2024; 16(8):e67054.

PMID: 39286663 PMC: 11403542. DOI: 10.7759/cureus.67054.


Long-term experiences with high-energy shock wave therapy in the management chronic phase Peyronie's disease using two different electromagnetic lithotripters.

Rassweiler J, Scheitlin W, Goezen A, Radecke F World J Urol. 2024; 42(1):124.

PMID: 38453751 PMC: 10920406. DOI: 10.1007/s00345-024-04792-x.

References
1.
Di Maida F, Cito G, Lambertini L, Valastro F, Morelli G, Mari A . The Natural History of Peyronie's Disease. World J Mens Health. 2020; 39(3):399-405. PMC: 8255406. DOI: 10.5534/wjmh.200065. View

2.
Levine L, Latchamsetty K . Treatment of erectile dysfunction in patients with Peyronie's disease using sildenafil citrate. Int J Impot Res. 2002; 14(6):478-82. DOI: 10.1038/sj.ijir.3900912. View

3.
Vardi Y, Levine L, Chen J, Hatzimouratidis K, Sohn M . Is there a place for conservative treatment in Peyronie's disease?. J Sex Med. 2009; 6(4):903-909. DOI: 10.1111/j.1743-6109.2009.01214.x. View

4.
Fernandez-Pascual E, Manfredi C, Torremade J, Peinado Ibarra F, Geli J, Romero-Otero J . Multicenter Prospective Study of Grafting With Collagen Fleece TachoSil in Patients With Peyronie's Disease. J Sex Med. 2020; 17(11):2279-2286. DOI: 10.1016/j.jsxm.2020.07.079. View

5.
Krishnappa P, Manfredi C, Sinha M, Arcaniolo D, Matippa P, Moncada I . Penile Modeling in Peyronie's Disease: A Systematic Review of the Literature. Sex Med Rev. 2022; 10(3):434-450. DOI: 10.1016/j.sxmr.2022.01.001. View